Search

Your search keyword '"Beelen, Dietrich"' showing total 168 results
Start Over Author "Beelen, Dietrich" Publication Year Range Last 3 years
168 results on '"Beelen, Dietrich"'

1. Fludarabine-treosulfan versus fludarabine-melphalan or busulfan-cyclophosphamide conditioning in older AML or MDS patients – A clinical trial to registry data comparison

Author

Beelen, Dietrich Wilhelm, Iacobelli, Simona, Koster, Linda, Eikema, Dirk-Jan, van Biezen, Anja, Stölzel, Friedrich, Ciceri, Fabio, Bethge, Wolfgang, Dreger, Peter, Wagner-Drouet, Eva-Maria, Reményi, Péter, Stelljes, Matthias, Markiewicz, Miroslaw, McLornan, Donal P., Yakoub-Agha, Ibrahim, and Mohty, Mohamad

Published
2024
Full Text
View/download PDF

6. Retrospective analysis of hematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: conditioning intensity matters

Author

Bruch, Peter-Martin, Dietrich, Sascha, Finel, Herve, Boumendil, Ariane, Greinix, Hildegard, Heinicke, Thomas, Bethge, Wolfgang, Beelen, Dietrich, Schmid, Christoph, Martin, Hans, Castagna, Luca, Scheid, Christof, Schäfer-Eckart, Kerstin, Bittenbring, Jörg, Finke, Jürgen, Sengeloev, Henrik, Heiblig, Mael, Cornelissen, Jan, Chevallier, Patrice, Mohty, Mohamad, Robinson, Stephen, Montoto, Silvia, and Dreger, Peter

Published
2023
Full Text
View/download PDF

9. Measurable residual disease (MRD) status before allogeneic hematopoietic cell transplantation impact on secondary acute myeloid leukemia outcome. A Study from the Acute Leukemia Working Party (ALWP) of the European society for Blood and Marrow Transplantation (EBMT)

Author

Maffini, Enrico, Labopin, Myriam, Beelen, Dietrich Wilhelm, Kroeger, Nicolaus, Arat, Mutlu, Wilson, Keith M. O., Bay, Jacques-Olivier, Ganser, Arnold, Martin, Hans, Passweg, Jakob, Kottaridis, Panagiotis D., Yakoub-Agha, Ibrahim, Porras, Rocio Parody, Wagner, Eva Maria, Esteve, Jordi, Lanza, Francesco, Nagler, Arnon, and Mohty, Mohamad

Published
2022
Full Text
View/download PDF

10. Allogeneic hematopoietic cell transplantation in patients with therapy-related myeloid neoplasm after breast cancer: a study of the Chronic Malignancies Working Party of the EBMT

Author

Nabergoj, Mitja, Mauff, Katya, Beelen, Dietrich, Ganser, Arnold, Kröger, Nicolaus, Stölzel, Friedrich, Finke, Jürgen, Passweg, Jakob, Cornelissen, Jan, Schub, Natalie, Veelken, Joan Hendrik, Beguin, Yves, Wilson, Keith, Zuckerman, Tsila, Hunault-Berger, Mathilde, Lioure, Bruno, Porras, Rocio Parody, Turlure, Pascal, Kerre, Tessa, Koster, Linda, Hayden, Patrick J., Onida, Francesco, Scheid, Christof, Chalandon, Yves, Robin, Marie, and Yakoub-Agha, Ibrahim

Published
2022
Full Text
View/download PDF

11. Impact of in vivo T-cell depletion in patients with myelodysplastic syndromes undergoing allogeneic hematopoietic stem cell transplant: a registry study from the Chronic Malignancies Working Party of the EBMT

Author

Forcade, Edouard, Chevret, Sylvie, Finke, Jürgen, Ehninger, Gerhard, Ayuk, Francis, Beelen, Dietrich, Koster, Linda, Ganser, Arnold, Volin, Liisa, Sengeloev, Henrik, Michallet, Mauricette, Tischer, Johanna, Jindra, Pavel, Cascon, Maria Jesús Pascual, Koc, Yener, Arat, Mutlu, Tomaszewska, Agnieszka, Hayden, Patrick, de Witte, Theo, Yakoub-Agha, Ibrahim, Kröger, Nicolaus, and Robin, Marie

Published
2022
Full Text
View/download PDF

12. Long-Term Results of Allogeneic Stem Cell Transplantation in Adult Ph- Negative High-Risk Acute Lymphoblastic Leukemia

Author

Beelen, Dietrich W., Arnold, Renate, Stelljes, Matthias, Alakel, Nael, Brecht, Arne, Bug, Gesine, Bunjes, Donald, Faul, Christoph, Finke, Jürgen, Franke, Georg-Nikolaus, Holler, Ernst, Kobbe, Guido, Kröger, Nicolaus, Rösler, Wolf, Scheid, Christof, Schönland, Stefan, Stadler, Michael, Tischer, Johanna, Wagner-Drouet, Eva, Wendelin, Knut, Brüggemann, Monika, Reiser, Lena, Hoelzer, Dieter, and Gökbuget, Nicola

Published
2022
Full Text
View/download PDF

13. Role of allogeneic transplantation in chronic myelomonocytic leukemia: an international collaborative analysis

Author

Robin, Marie, de Wreede, Liesbeth C., Padron, Eric, Bakunina, Katerina, Fenaux, Pierre, Koster, Linda, Nazha, Aziz, Beelen, Dietrich W., Rampal, Raajit K., Sockel, Katja, Komrokji, Rami S., Gagelmann, Nico, Eikema, Dirk-Jan, Radujkovic, Aleksandar, Finke, Jürgen, Potter, Victoria, Killick, Sally B., Legrand, Faezeh, Solary, Eric, Broom, Angus, Garcia-Manero, Guillermo, Rizzoli, Vittorio, Hayden, Patrick, Patnaik, Mrinal M., Onida, Francesco, Yakoub-Agha, Ibrahim, and Itzykson, Raphael

Published
2022
Full Text
View/download PDF

14. GLA/DRST real-world outcome analysis of CAR T-cell therapies for large B-cell lymphoma in Germany

Author

Bethge, Wolfgang A., Martus, Peter, Schmitt, Michael, Holtick, Udo, Subklewe, Marion, von Tresckow, Bastian, Ayuk, Francis, Wagner-Drouet, Eva Marie, Wulf, Gerald G., Marks, Reinhard, Penack, Olaf, Schnetzke, Ulf, Koenecke, Christian, von Bonin, Malte, Stelljes, Matthias, Glass, Bertram, Baldus, Claudia D., Vucinic, Vladan, Mougiakakos, Dimitrios, Topp, Max, Fante, Matthias A., Schroers, Roland, Bayir, Lale, Borchmann, Peter, Buecklein, Veit, Hasenkamp, Justin, Hanoun, Christine, Thomas, Simone, Beelen, Dietrich W., Lengerke, Claudia, Kroeger, Nicolaus, and Dreger, Peter

Published
2022
Full Text
View/download PDF

16. Health-Related Complications during Follow-Up and Their Impact on Blood Cancer Survivors: Results from the "Aftercare in Blood Cancer Survivors" (ABC) Study.

Author

Baum, Julia, Lax, Hildegard, Lehmann, Nils, Merkel-Jens, Anja, Beelen, Dietrich W., Jöckel, Karl-Heinz, and Dührsen, Ulrich

Subjects
SECONDARY primary cancer, BASAL cell carcinoma, CARDIOVASCULAR diseases, CANCER survivors, MULTIPLE myeloma
Abstract

Introduction: Blood cancer survivors are at increased risk for medical complications. Methods: Our questionnaire-based study involved 1,551 blood cancer survivors with a ≥3-year interval since the last intense treatment. Its goal was to quantify health-related complications during follow-up and assess their impact on the patients' lives. Results: A total of 20.4% of the responding survivors reported a disease relapse, most often in indolent lymphomas. Second primary malignancies occurred in 14.1%, primarily in lymphoma and allogeneic transplantation survivors. The most frequent malignancy was basal cell carcinoma of the skin, but myeloid malignancies, melanoma, bladder, head-and-neck, and thyroid cancer also appeared disproportionately frequent. An increased infection rate was reported by 43.7%, most often after allogeneic transplantation. New cardiovascular diseases were reported by 30.2%, with a high rate of thromboembolic events in multiple myeloma (MM) and myeloproliferative diseases. Polyneuropathies were reported by 39.1%, most often by survivors with a history of MM or aggressive lymphoma. Disease relapse was perceived as the highest burden, followed by second primary malignancy, increased infection frequency, and polyneuropathy. In each area investigated, the range of perceived severities was wide. Conclusions: Health-related complications are frequent during blood cancer follow-up, with significant repercussions on the patients' lives. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

17. Influence of pretransplant inflammatory bowel disease on the outcome of allogeneic hematopoietic stem cell transplantation: a matched-pair analysis study from the Transplant Complications Working Party (TCWP) of the EBMT

Author

Peric, Zinaida, Peczynski, Christophe, Polge, Emmanuelle, Kröger, Nicolaus, Sengeloev, Henrik, Radujkovic, Aleksandar, Helbig, Grzegorz, Russell, Nigel, Bunjes, Donald, Socié, Gerard, Potter, Victoria, Beelen, Dietrich, Crawley, Charles, Bloor, Adrian, Finke, Jürgen, Schoemans, Helene, Penack, Olaf, Snowden, John A., Koenecke, Christian, and Basak, Grzegorz W.

Published
2021
Full Text
View/download PDF

18. Impact of prior JAK-inhibitor therapy with ruxolitinib on outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis: a study of the CMWP of EBMT

Author

Kröger, Nicolaus, Sbianchi, Giulia, Sirait, Tiarlan, Wolschke, Christine, Beelen, Dietrich, Passweg, Jakob, Robin, Marie, Vrhovac, Radovan, Helbig, Grzegorz, Sockel, Katja, Conneally, Eibhlin, Rubio, Marie Thérèse, Beguin, Yves, Finke, Jürgen, Bernasconi, Paolo, Morozova, Elena, Clausen, Johannes, von dem Borne, Peter, Schaap, Nicolaas, Schroyens, Wilfried, Patriarca, Francesca, Di Renzo, Nicola, Yeğin, Zeynep Arzu, Hayden, Patrick, McLornan, Donal, and Yakoub-Agha, Ibrahim

Published
2021
Full Text
View/download PDF

20. A dynamic time‐to‐event model for prediction of acute graft‐versus‐host disease in patients after allogeneic hematopoietic stem cell transplantation

Author

Och, Katharina, primary, Turki, Amin T., additional, Götz, Katharina M., additional, Selzer, Dominik, additional, Brossette, Christian, additional, Theobald, Stefan, additional, Braun, Yvonne, additional, Graf, Norbert, additional, Rauch, Jochen, additional, Rohm, Kerstin, additional, Weiler, Gabriele, additional, Kiefer, Stephan, additional, Schwarz, Ulf, additional, Eisenberg, Lisa, additional, Pfeifer, Nico, additional, Ihle, Matthias, additional, Grandjean, Andrea, additional, Fix, Sonja, additional, Riede, Claudia, additional, Rissland, Jürgen, additional, Smola, Sigrun, additional, Beelen, Dietrich W., additional, Kaddu‐Mulindwa, Dominic, additional, Bittenbring, Jörg, additional, and Lehr, Thorsten, additional

Published
2023
Full Text
View/download PDF

21. P352: PROPHYLACTIC AND PREEMPTIVE USE OF DLI COMPARE FAVOURABLY TO THEIR THERAPEUTIC USE IN ADULT ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) – RESULTS OF A MULTICENTRE RETROSPECTIVE STUDY

Author

Haupt, Maik, primary, Jäkel, Nadja, additional, Wachsmuth, Maria, additional, Stadler, Michael, additional, Beelen, Dietrich, additional, Finke, Juergen, additional, Alakel, Nael, additional, Hemmati, Philipp, additional, Schönland, Stefan, additional, Bethge, Wolfgang, additional, Wulf, Gerald, additional, Wolff, Daniel, additional, Maria Tischer, Johanna, additional, Wagner-Drouet, Eva, additional, Brandt, Anna, additional, Kröger, Nicolaus, additional, Vucinic, Vladan, additional, Bärmann, Ben-Niklas, additional, Brüggemann, Monika, additional, Gromann, Cora, additional, Müller-Tidow, Carsten, additional, Gökbuget, Nicola, additional, and Mueller, Lutz, additional

Published
2023
Full Text
View/download PDF

22. Correction to: Idelalisib treatment prior to allogeneic stem cell transplantation for patients with chronic lymphocytic leukemia: a report from the EBMT chronic malignancies working party

Author

Schetelig, Johannes, Chevallier, Patrice, van Gelder, Michel, Hoek, Jennifer, Hermine, Olivier, Chakraverty, Ronjon, Browne, Paul, Milpied, Noel, Malagola, Michele, Socié, Gerard, Delgado, Julio, Deconinck, Eric, Damaj, Ghandi, Maury, Sebastian, Beelen, Dietrich, Quoc, Stéphanie Nguyen, Shankara, Paneesha, Brecht, Arne, Mayer, Jiri, Hunault-Berger, Mathilde, Bittenbring, Jörg, Thieblemont, Catherine, Lepretre, Stéphane, Baldauf, Henning, de Wreede, Liesbeth C., Tournilhac, Olivier, Yakoub-Agha, Ibrahim, Kröger, Nicolaus, and Dreger, Peter

Published
2022
Full Text
View/download PDF

23. Correction: Idelalisib exposure before allogeneic stem cell transplantation in patients with follicular lymphoma: an EBMT survey

Author

Sellner, Leopold, Schetelig, Johannes, Koster, Linda, Choi, Goda, Blaise, Didier, Beelen, Dietrich, Schianca, Fabrizio Carnevale, Passweg, Jakob, Schanz, Urs, Gyan, Emmanuel, Sora, Federica, Kröger, Nicolaus, Wulf, Gerald. G., Van Gorkom, Gwendolyn, Mayer, Jiri, Orvain, Corentin, Bourhis, Jean Henri, Jindra, Pavel, Potter, Victoria, Zallio, Francesco, Vandenberghe, Elisabeth, Robinson, Stephen, Hayden, Patrick J., Yakoub-Agha, Ibrahim, Montoto, Silvia, and Dreger, Peter

Published
2021
Full Text
View/download PDF

24. Impact of prior JAK-inhibitor therapy with ruxolitinib on outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis: a study of the CMWP of EBMT

Author

Kröger, Nicolaus, Sbianchi, Giulia, Sirait, Tiarlan, Wolschke, Christine, Beelen, Dietrich, Passweg, Jakob, Robin, Marie, Vrhovac, Radovan, Helbig, Grzegorz, Sockel, Katja, Conneally, Eibhlin, Rubio, Marie Thérèse, Beguin, Yves, Finke, Jürgen, Bernasconi, Paolo, Morozova, Elena, Clausen, Johannes, von dem Borne, Peter, Schaap, Nicolaas, Schroyens, Wilfried, Patriarca, Francesca, Di Renzo, Nicola, Yeğin, Zeynep Arzu, Hayden, Patrick, McLornan, Donal, and Yakoub-Agha, Ibrahim

Abstract

JAK1/2 inhibitor ruxolitinib (RUX) is approved in patients with myelofibrosis but the impact of pretreatment with RUX on outcome after allogeneic hematopoietic stem cell transplantation (HSCT) remains to be determined. We evaluated the impact of RUX on outcome in 551 myelofibrosis patients who received HSCT without (n= 274) or with (n= 277) RUX pretreatment. The overall leukocyte engraftment on day 45 was 92% and significantly higher in RUX responsive patients than those who had no or lost response to RUX (94% vs. 85%, p= 0.05). The 1-year non-relapse mortality was 22% without significant difference between the arms. In a multivariate analysis (MVA) RUX pretreated patients with ongoing spleen response at transplant had a significantly lower risk of relapse (8.1% vs. 19.1%; p= 0.04)] and better 2-year event-free survival (68.9% vs. 53.7%; p= 0.02) in comparison to patients without RUX pretreatment. For overall survival the only significant factors were age > 58 years (p= 0.03) and HLA mismatch donor (p= 0.001). RUX prior to HSCT did not negatively impact outcome after transplantation and patients with ongoing spleen response at time of transplantation had best outcome.

Published
2024
Full Text
View/download PDF

25. Treosulfan compared with <scp>reduced‐intensity</scp> busulfan improves allogeneic hematopoietic cell transplantation outcomes of older acute myeloid leukemia and myelodysplastic syndrome patients: Final analysis of a prospective randomized trial

Author

Beelen, Dietrich, Stelljes, Matthias, Reményi, Péter, Wagner‐Drouet, Eva‐Maria, Dreger, Peter, Bethge, Wolfgang, Ciceri, Fabio, Stölzel, Friedrich, Junghanß, Christian, Labussiere‐Wallet, Hélène, Schaefer‐Eckart, Kerstin, Grigoleit, Goetz U., Scheid, Christof, Patriarca, Francesca, Rambaldi, Alessandro, Niederwieser, Dietger, Hilgendorf, Inken, Russo, Domenico, Socié, Gérard, Holler, Ernst, Glass, Bertram, Casper, Jochen, Wulf, Gerald, Basara, Nadezda, Bieniaszewska, Maria, Stuhler, Gernot, Verbeek, Mareike, La Rocca, Ursula, Finke, Jürgen, Benedetti, Fabio, Pichlmeier, Uwe, Klein, Anja, Baumgart, Joachim, Markiewicz, Miroslaw, and Rocca, Ursula La

Subjects
Leukemia, Myeloid, Acute, Transplantation Conditioning, Myelodysplastic Syndromes, Medizin, Hematopoietic Stem Cell Transplantation, Graft vs Host Disease, Humans, Prospective Studies, Hematology, Middle Aged, Busulfan, Vidarabine, Aged
Abstract

The phase III study was designed to compare event-free survival (EFS) after treosulfan-based conditioning with a widely applied reduced-intensity conditioning (RIC) busulfan regimen in older or comorbid patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) undergoing allogeneic hematopoietic cell transplantation (HCT). A previously reported confirmatory interim analysis of the randomized clinical study including 476 patients demonstrated statistically significant noninferiority for treosulfan with clinically meaningful improvement in EFS. Here, the final study results and pre-specified subgroup analyses of all 570 randomized patients with completed longer-term follow-up are presented. Patients presenting HCT-specific comorbidity index >2 or aged >= 50 years were randomly assigned (1:1) to intravenous (IV) fludarabine with either treosulfan (30 g/m(2) IV) or busulfan (6.4 mg/kg IV) after stratification by disease risk group, donor type, and participating institution. The primary endpoint was EFS with disease recurrence, graft failure, or death from any cause as events. EFS of patients (median age 60 years) was superior after treosulfan compared to RIC busulfan: 36-months-EFS rate 59.5% (95% CI, 52.2-66.1) vs. 49.7% (95% CI, 43.3-55.7) with a hazard ratio (HR) of 0.64 (95% CI, 0.49-0.84), p = 0.0006. Likewise, overall survival (OS) with treosulfan was superior compared to busulfan: 36-month-OS rate 66.8% vs. 56.3%; HR 0.64 (95% CI, 0.48-0.87), p = 0.0037. Post hoc analyses revealed that these differences were consistent with the confirmatory interim analysis, and thereby the treosulfan regimen appears particularly suitable for older AML and MDS patients.

Published
2022

26. Supplementary Data from Evaluation of Trends and Prognosis Over Time in Patients with AML Relapsing After Allogeneic Hematopoietic Cell Transplant Reveals Improved Survival for Young Patients in Recent Years

Author

Bazarbachi, Ali, primary, Schmid, Christoph, primary, Labopin, Myriam, primary, Beelen, Dietrich, primary, Wolfgang Blau, Igor, primary, Potter, Victoria, primary, Niittyvuopio, Riitta, primary, Socié, Gerard, primary, Blaise, Didier, primary, Sanz, Jaime, primary, Ciceri, Fabio, primary, Abou Dalle, Iman, primary, Spyridonidis, Alexandros, primary, Bug, Gesine, primary, Esteve, Jordi, primary, Savani, Bipin N., primary, Nagler, Arnon, primary, and Mohty, Mohamad, primary

Published
2023
Full Text
View/download PDF

27. Time series clustering of T cell subsets dissects heterogeneity in immune reconstitution and clinical outcomes among MUD-HCT patients receiving ATG or PTCy

Author

Leserer, Saskia, primary, Graf, Theresa, additional, Franke, Martina, additional, Bogdanov, Rashit, additional, Arrieta-Bolaños, Esteban, additional, Buttkereit, Ulrike, additional, Leimkühler, Nils, additional, Fleischhauer, Katharina, additional, Reinhardt, Hans Christian, additional, Beelen, Dietrich W., additional, and Turki, Amin T., additional

Published
2023
Full Text
View/download PDF

28. Allogeneic Hematopoietic Cell Transplantation vs Standard Consolidation Chemotherapy in Patients With Intermediate-Risk Acute Myeloid Leukemia

Author

Bornhäuser, Martin, primary, Schliemann, Christoph, additional, Schetelig, Johannes, additional, Röllig, Christoph, additional, Kramer, Michael, additional, Glass, Bertram, additional, Platzbecker, Uwe, additional, Burchert, Andreas, additional, Hänel, Mathias, additional, Müller, Lutz P., additional, Klein, Stefan, additional, Bug, Gesine, additional, Beelen, Dietrich, additional, Rösler, Wolf, additional, Schäfer-Eckart, Kerstin, additional, Schmid, Christoph, additional, Jost, Edgar, additional, Lenz, Georg, additional, Tischer, Johanna, additional, Spiekermann, Karsten, additional, Pfirrmann, Markus, additional, Serve, Hubert, additional, Stölzel, Friedrich, additional, Alakel, Nael, additional, Middeke, Jan Moritz, additional, Thiede, Christian, additional, Ehninger, Gerhard, additional, Berdel, Wolfgang E., additional, and Stelljes, Matthias, additional

Published
2023
Full Text
View/download PDF

29. XplOit : An Ontology-Based Data Integration Platform Supporting the Development of Predictive Models for Personalized Medicine

Author

Weiler, Gabriele, Schwarz, Ulf, Rauch, Jochen, Rohm, Kerstin, Lehr, Thorsten, Theobald, Stefan, Kiefer, Stephan, Götz, Katharina, Och, Katharina, Pfeifer, Nico, Handl, Lisa, Smola, Sigrun, Ihle, Matthias, Turki, Amin T., Beelen, Dietrich W., Rissland, Jürgen, Bittenbring, Jörg, and Graf, Norbert

Subjects
Predictive models, semantic integration, semantic data annotation
Published
2023
Full Text
View/download PDF

30. Allogeneic Hematopoietic Cell Transplantation vs Standard Consolidation Chemotherapy in Patients with Intermediate-Risk Acute Myeloid Leukemia : A Randomized Clinical Trial

Author

Bornhäuser, Martin, Schliemann, Christoph, Schetelig, Johannes, Röllig, Christoph, Kramer, Michael, Glass, Bertram, Platzbecker, Uwe, Burchert, Andreas, Hänel, Mathias, Müller, Lutz P., Klein, Stefan, Bug, Gesine, Beelen, Dietrich, Rösler, Wolf, Schäfer-Eckart, Kerstin, Schmid, Christoph, Jost, Edgar, Lenz, Georg, Tischer, Johanna, Spiekermann, Karsten, Pfirrmann, Markus, Serve, Hubert, Stölzel, Friedrich, Alakel, Nael, Middeke, Jan Moritz, Thiede, Christian, Ehninger, Gerhard, Berdel, Wolfgang E., and Stelljes, Matthias

Subjects
Cancer Research, Oncology, Medizin
Abstract

ImportanceThe ideal postremission strategy in intermediate-risk acute myeloid leukemia (AML) in first complete remission (CR) has been a matter of debate.ObjectiveTo explore the optimal therapy for patients with intermediate-risk AML after first complete remission.Design, Settings, and ParticipantsThis investigator-initiated, open-label, 2-armed, phase 3 randomized clinical trial assessed patients at 16 hospitals in Germany from February 2, 2011, until July 1, 2018. Key eligibility criteria included cytogenetically defined intermediate-risk AML according to Medical Research Council classification, first CR or CR with incomplete blood cell count recovery after conventional induction therapy, age of 18 to 60 years, and availability of a human leukocyte antigen (HLA)–matched sibling or unrelated donor. A detailed statistical analysis plan was written and finalized on July 7, 2020. Data were exported for analysis on April 13, 2021.InterventionsPatients were randomized 1:1 to receive allogeneic hematopoietic cell transplantation (HCT) or high-dose cytarabine for consolidation and salvage HCT only in case of relapse. Strata for randomization included age (18-40 vs 41-60 years), NPM1 and CEBPA variation status, and donor type (unrelated vs related).Main Outcomes and MeasuresEnd points included overall-survival as the primary outcome and disease-free survival, cumulative incidence of relapse, treatment-related mortality, and quality of life measured according to the Medical Outcomes Study 36-Item Short-Form Health Survey as secondary outcomes.ResultsA total of 143 patients (mean [SD] age, 48.2 [9.8] years; 81 [57%] male) with AML who fulfilled the eligibility criteria were randomized. In the intention-to-treat analysis, the probability of survival at 2 years was 74% (95% CI, 62%-83%) after primary allogeneic HCT and 84% (95% CI, 73%-92%) after consolidation chemotherapy (P = .22). Disease-free survival after HCT at 2 years was 69% (95% CI, 57%-80%) compared with 40% (95% CI, 28%-53%) after consolidation chemotherapy (P = .001). Allogeneic HCT during the first CR was associated with a cumulative incidence of relapse at 2 years of 20% (95% CI, 13%-31%) compared with 58% (95% CI, 47%-71%; P P = .005). Similar outcomes were observed when analyses were confined to the 96 patients at intermediate risk according to the European Leukemia Network classification. Most importantly, all 41 patients relapsing after consolidation chemotherapy (36 hematologic, 4 molecular, and 1 extramedullary) proceeded to allogeneic HCT. No significant differences in health-related quality of life measures were observed between groups.Conclusions and RelevancePrimary allogeneic HCT during first CR was not associated with superior overall survival compared with consolidation chemotherapy in patients 60 years or younger with intermediate-risk AML during the first CR and an available donor.Trial RegistrationClinicalTrials.gov Identifier: NCT01246752

Published
2023

31. Retrospective analysis of hematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: conditioning intensity matters

Author

Bruch, Peter-Martin, primary, Dietrich, Sascha, additional, Finel, Herve, additional, Boumendil, Ariane, additional, Greinix, Hildegard, additional, Heinicke, Thomas, additional, Bethge, Wolfgang, additional, Beelen, Dietrich, additional, Schmid, Christoph, additional, Martin, Hans, additional, Castagna, Luca, additional, Scheid, Christof, additional, Schäfer-Eckart, Kerstin, additional, Bittenbring, Jörg, additional, Finke, Jürgen, additional, Sengeloev, Henrik, additional, Heiblig, Mael, additional, Cornelissen, Jan, additional, Chevallier, Patrice, additional, Mohty, Mohamad, additional, Robinson, Stephen, additional, Montoto, Silvia, additional, and Dreger, Peter, additional

Published
2022
Full Text
View/download PDF

32. Allogeneic hematopoietic cell transplantation in acute myeloid leukemia with intermediate-risk - results of the randomized ETAL-1 trial

Author

Bornhauser, Martin, primary, Schliemann, Christoph, additional, Schetelig, Johannes, additional, Röllig, Christoph, additional, Kramer, Michael, additional, Glass, Bertram, additional, Platzbecker, Uwe, additional, Burchert, Andreas, additional, Hänel, Mathias, additional, Muller, Lutz, additional, Klein, Stefan, additional, Bug, Gesine, additional, Beelen, Dietrich, additional, Rösler, Wolf, additional, Schäfer-Eckart, Kerstin, additional, Schmid, Christoph, additional, Jost, Edgar, additional, Lenz, Georg, additional, Tischer, Johanna, additional, Spiekermann, Karsten, additional, Pfirrmann, Markus, additional, Serve, Hubert, additional, Stölzel, Friedrich, additional, Alakel, Nael, additional, Middeke, Jan Moritz, additional, Thiede, Christian, additional, Ehninger, Gerhard, additional, Berdel, Wolfgang, additional, and Stelljes, Matthias, additional

Published
2022
Full Text
View/download PDF

33. Treosulfan compared with reduced‐intensity busulfan improves allogeneic hematopoietic cell transplantation outcomes of older acute myeloid leukemia and myelodysplastic syndrome patients: Final analysis of a prospective randomized trial

Author

Beelen, Dietrich W., primary, Stelljes, Matthias, additional, Reményi, Péter, additional, Wagner‐Drouet, Eva‐Maria, additional, Dreger, Peter, additional, Bethge, Wolfgang, additional, Ciceri, Fabio, additional, Stölzel, Friedrich, additional, Junghanß, Christian, additional, Labussiere‐Wallet, Hélène, additional, Schaefer‐Eckart, Kerstin, additional, Grigoleit, Goetz U., additional, Scheid, Christof, additional, Patriarca, Francesca, additional, Rambaldi, Alessandro, additional, Niederwieser, Dietger, additional, Hilgendorf, Inken, additional, Russo, Domenico, additional, Socié, Gérard, additional, Holler, Ernst, additional, Glass, Bertram, additional, Casper, Jochen, additional, Wulf, Gerald, additional, Basara, Nadezda, additional, Bieniaszewska, Maria, additional, Stuhler, Gernot, additional, Verbeek, Mareike, additional, La Rocca, Ursula, additional, Finke, Jürgen, additional, Benedetti, Fabio, additional, Pichlmeier, Uwe, additional, Klein, Anja, additional, Baumgart, Joachim, additional, and Markiewicz, Miroslaw, additional

Published
2022
Full Text
View/download PDF

34. Akute Myeloische Leukämie (AML)

Author

Schweizerische Gesellschaft Für Hämatologie, Schlenk, Richard Friedrich, Heuser, Michael, Schweizerische Gesellschaft Für Medizinische Onkologie, Gesellschaft Für Pädiatrische Onkologie Und Hämatologie, Manz, Markus G., Reinhardt, Dirk, Österreichische Gesellschaft Für Hämatologie & Medizinische Onkologie, Greil, Richard, Braess, Jan, Deutsche Gesellschaft Für Hämatologie Und Medizinische Onkologie, Beelen, Dietrich W., Passweg, Jakob R., and Röllig, Christoph

Subjects
Medizin und Gesundheit
Published
2022
Full Text
View/download PDF

35. Favourable Outcome after Treosulfan Based Conditioning of Patients Receiving an Allogeneic Hematopoietic Cell Transplantation (AlloHCT) for the Treatment of a Myelodysplastic Syndrome (MDS)

Author

Stelljes, Matthias, primary, Trenschel, Rudolf, additional, Beelen, Dietrich Wilhelm, additional, Markiewicz, Miroslaw, additional, Wagner, Eva Maria, additional, Bethge, Wolfgang, additional, Remenyi, Peter, additional, Niederwieser, Dietger, additional, Grigoleit, Goetz, additional, Schaefer-Eckart, Kerstin, additional, Stölzel, Friedrich, additional, Ciceri, Fabio, additional, Dreger, Peter, additional, Junghanß, Christian, additional, Holler, Ernst, additional, Rambaldi, Alessandro, additional, Russo, Domenico, additional, Verbeek, Mareike, additional, Casper, Jochen, additional, Patriarca, Francesca, additional, Bieniaszewska, Maria, additional, Glass, Bertram, additional, Scheid, Christoph, additional, Basara, Nadezda, additional, Finke, Jürgen, additional, Hilgendorf, Inken, additional, Labussière-Wallet, Hélène, additional, Stuhler, Gernot, additional, and Schroeder, Thomas, additional

Published
2022
Full Text
View/download PDF

36. Favourable Outcome after Treosulfan Based Conditioning in Patients Undergoing an Allogeneic Hematopoietic Cell Transplantation (alloHCT) for the Treatment of Acute Myleloid Leukaemia (AML): A Subgroup Analysis of the Randomized Phase III MC-Fludt.14/L Trial

Author

Stölzel, Friedrich, primary, Stelljes, Matthias, additional, Beelen, Dietrich Wilhelm, additional, Markiewicz, Miroslaw, additional, Remenyi, Peter, additional, Dreger, Peter, additional, Ciceri, Fabio, additional, Wagner-Drouet, Eva-Maria, additional, Junghanss, Christian, additional, Scheid, Christoph, additional, Patriarca, Francesca, additional, Socié, Gerard, additional, Hilgendorf, Inken, additional, Rambaldi, Alessandro, additional, Schaefer-Eckart, Kerstin, additional, Russo, Domenico, additional, Grigoleit, Goetz, additional, Wulf, Gerald, additional, Basara, Nadezda, additional, Glass, Bertram, additional, Stuhler, Gernot, additional, Bieniaszewska, Maria, additional, Casper, Jochen, additional, Holler, Ernst, additional, Benedetti, Fabio, additional, Iori, Anna Paola, additional, Trenschel, Rudolf, additional, and Bethge, Wolfgang, additional

Published
2022
Full Text
View/download PDF

38. Measurable residual disease, FLT3‐ITD mutation, and disease status have independent prognostic influence on outcome of allogeneic stem cell transplantation in NPM1‐mutated acute myeloid leukemia

Author

Al Hamed, Rama, primary, Labopin, Myriam, additional, Daguindau, Etienne, additional, Niittyvuopio, Riitta, additional, Huynh, Anne, additional, Socié, Gerard, additional, Srour, Micha, additional, Henri Bourhis, Jean, additional, Kröger, Nicolaus, additional, Tholouli, Eleni, additional, Choi, Goda, additional, Poiré, Xavier, additional, Martin, Hans, additional, Rubio, Marie‐Thérèse, additional, Jindra, Pavel, additional, Blaise, Didier, additional, Beelen, Dietrich, additional, Labussière‐Wallet, Hélène, additional, Nagler, Arnon, additional, Bazarbachi, Ali, additional, and Mohty, Mohamad, additional

Published
2022
Full Text
View/download PDF

39. Combined Analysis of Early CD4+ T Cell Counts and CMV Serostatus May Improve CMV Risk Assessment after Allogeneic Hematopoietic Cell Transplantation

Author

Leserer, Saskia, Arrieta-Bolaños, Esteban, Buttkereit, Ulrike, Beelen, Dietrich W., and Turki, Amin T.

Subjects
Adult, CD4-Positive T-Lymphocytes, Male, CMV risk assessment, Adolescent, QH301-705.5, Cytomegalovirus, unsupervised learning, Risk Assessment, clustering -- unsupervised learning -- CMV risk assessment -- CMV reactivation -- CMV serostatus -- CD4+ T helper cells -- immune reconstitution -- T cell reconstitution -- R+ serostatus, Article, Young Adult, CMV serostatus, CD4+ T helper cells, Humans, Transplantation, Homologous, Lymphocyte Count, ddc:610, Biology (General), Aged, CMV reactivation, Incidence, T cell reconstitution, Hematopoietic Stem Cell Transplantation, immune reconstitution, Middle Aged, Medizinische Fakultät » Universitätsklinikum Essen » Institut für Zelltherapeutische Forschung, Prognosis, Medizinische Fakultät » Universitätsklinikum Essen » Klinik für Hämatologie und Stammzelltransplantation, Cytomegalovirus Infections, R+ serostatus, Female, clustering
Abstract

The incidence and severity of viral complications after cellular therapy are highly variable. Recent publications describe relevant interactions between the human Cytomegalovirus (CMV) and host immunity in recipients of allogeneic hematopoietic cell transplantation (HCT). Although immune monitoring is routinely performed in HCT patients, validated cut-off levels correlating with transplant outcomes such as survival or CMV reactivation are mostly limited to day +100, which is later than the median time for CMV reactivation in the absence of medical prophylaxis. To address this gap in early risk assessment, we applied an unsupervised machine learning technique based on clustering of day +30 CD4+ helper T cell count data, and identified relevant cut-off levels within the diverse spectrum of early CD4+ reconstitution. These clusters were stratified for CMV recipient serostatus to identify early risk groups that predict clinical HCT outcome. Indeed, the new risk groups predicted subsequent clinical events such as NRM, OS, and high CMV peak titers better than the most established predictor, i.e., the positive CMV recipient serostatus (R+). More specifically, patients from the R+/low CD4+ subgroup strongly associated with high CMV peak titers and increased 3-year NRM (subdistribution hazard ratio (SHR) 10.1, 95% CI 1.38–73.8, p = 0.023), while patients from the R-/very high CD4+ subgroup showed comparable NRM risks (SHR 9.57, 95% CI 1.12–81.9, p = 0.039) without such an association. In short, our study established novel cut-off levels for early CD4+ T cells via unsupervised learning and supports the integration of host cellular immunity into clinical risk-assessment after HCT in the context of CMV reactivation.

Published
2021

40. Impact of CMV reactivation on relapse of acute myeloid leukemia after HCT is dependent on disease stage and ATG

Author

Turki, Amin T., primary, Tsachakis-Mück, Nikolaos, additional, Leserer, Saskia, additional, Crivello, Pietro, additional, Liebregts, Tobias, additional, Betke, Luisa, additional, Alashkar, Ferras, additional, Leimkühler, Nils B., additional, Trilling, Mirko, additional, Fleischhauer, Katharina, additional, and Beelen, Dietrich W., additional

Published
2021
Full Text
View/download PDF

41. Correction to: Idelalisib treatment prior to allogeneic stem cell transplantation for patients with chronic lymphocytic leukemia: a report from the EBMT chronic malignancies working party

Author

Schetelig, Johannes, primary, Chevallier, Patrice, additional, van Gelder, Michel, additional, Hoek, Jennifer, additional, Hermine, Olivier, additional, Chakraverty, Ronjon, additional, Browne, Paul, additional, Milpied, Noel, additional, Malagola, Michele, additional, Socié, Gerard, additional, Delgado, Julio, additional, Deconinck, Eric, additional, Damaj, Ghandi, additional, Maury, Sebastian, additional, Beelen, Dietrich, additional, Quoc, Stéphanie Nguyen, additional, Shankara, Paneesha, additional, Brecht, Arne, additional, Mayer, Jiri, additional, Hunault-Berger, Mathilde, additional, Bittenbring, Jörg, additional, Thieblemont, Catherine, additional, Lepretre, Stéphane, additional, Baldauf, Henning, additional, de Wreede, Liesbeth C., additional, Tournilhac, Olivier, additional, Yakoub-Agha, Ibrahim, additional, Kröger, Nicolaus, additional, and Dreger, Peter, additional

Published
2021
Full Text
View/download PDF

42. Late Non-Relapse Mortality (NRM) after Standard-of-Care (SOC) CAR-T Cell Therapy for Large B-Cell Lymphoma (LBCL): Frequency, Causes, and Risk Factors.a GLA/DRST Real World Analysis

Author

Dreger, Peter, primary, Schubert, Maria-Luisa, additional, Holtick, Udo, additional, Subklewe, Marion, additional, Bastian, von Tresckow, additional, Ayuk, Francis A., additional, Wagner, Eva Maria, additional, Wulf, Gerald, additional, Marks, Reinhard, additional, Penack, Olaf, additional, Schnetzke, Ulf, additional, Koenecke, Christian, additional, Von Bonin, Malte, additional, Stelljes, Matthias, additional, Glass, Bertram, additional, Baldus, Claudia D., additional, Vucinic, Vladan, additional, Mougiakakos, Dimitrios, additional, Topp, Max, additional, Wolff, Daniel, additional, Schroers, Roland, additional, Borchmann, Peter, additional, Rejeski, Kai, additional, Hanoun, Christine, additional, Lengerke, Claudia, additional, Thomas, Simone, additional, Beelen, Dietrich W., additional, Kröger, Nicolaus, additional, and Bethge, Wolfgang A, additional

Published
2021
Full Text
View/download PDF

43. Allogeneic Stem Cell Transplantation in Patients Aged ≥70 Years: Epidemiology, Outcomes, and Risk Factors Based on the German Registry for Stem Cell Transplantation (DRST)

Author

Weller, Jan Frederic, primary, Kaufmann, Louisa, additional, Lengerke, Claudia, additional, Finke, Jürgen, additional, Schetelig, Johannes, additional, Platzbecker, Uwe, additional, Einsele, Hermann, additional, Beelen, Dietrich W., additional, Faul, Christoph, additional, Stelljes, Matthias, additional, Dreger, Peter, additional, Blau, Igor Wolfgang, additional, Wulf, Gerald, additional, Tischer, Johanna, additional, Scheid, Christof, additional, Elmaagacli, Ahmet, additional, Neidlinger, Helga, additional, Frank, Sandra, additional, Bornhäuser, Martin, additional, Bethge, Wolfgang A, additional, Fleischhauer, Katharina, additional, Kröger, Nicolaus, additional, and Christopeit, Maximilian, additional

Published
2021
Full Text
View/download PDF

44. Allogeneic Hematopoietic Cell Transplantation in Patients ≤ 60 Years with Intermediate-Risk Acute Myeloid Leukemia in First Remission - Results of the Randomized Etal-1 Trial-

Author

Bornhaeuser, Martin, primary, Schliemann, Christoph, additional, Schetelig, Johannes, additional, Rollig, Christoph, additional, Kramer, Michael, additional, Glass, Bertram, additional, Platzbecker, Uwe, additional, Burchert, Andreas, additional, Haenel, Mathias, additional, Mueller, Lutz Peter, additional, Klein, Stefan, additional, Bug, Gesine, additional, Beelen, Dietrich W., additional, Roesler, Wolf, additional, Schaefer-Eckart, Kerstin, additional, Schmid, Christoph, additional, Jost, Edgar, additional, Lenz, Georg, additional, Tischer, Johanna, additional, Spiekermann, Karsten, additional, Pfirrmann, Markus, additional, Serve, Hubert, additional, Stoelzel, Friedrich, additional, Alakel, Nael, additional, Ehninger, Gerhard, additional, Berdel, Wolfgang E., additional, and Stelljes, Matthias, additional

Published
2021
Full Text
View/download PDF

45. Reduced Intensity Stem Cell Transplantation for Accelerated-Phase Myelofibrosis

Author

Gagelmann, Nico, primary, Badbaran, Anita, additional, Ditschkowski, Markus, additional, Panagiota, Victoria, additional, Cassinat, Bruno, additional, Heuser, Michael, additional, Thol, Felicitas, additional, Wolschke, Christine, additional, Salit, Rachel B., additional, Robin, Marie, additional, Beelen, Dietrich W., additional, Scott, Bart L., additional, and Kroeger, Nicolaus, additional

Published
2021
Full Text
View/download PDF

46. Standard of Care CAR-T Cell Therapy for Large B-Cell Lymphoma (LBCL): Does Bridging Efficacy Matter? a German GLA/DRST Real World Analysis

Author

Bethge, Wolfgang A, primary, Martus, Peter, additional, Schmitt, Michael, additional, Holtick, Udo, additional, Borchmann, Peter, additional, Subklewe, Marion, additional, Rejeski, Kai, additional, von Tresckow, Bastian, additional, Ayuk, Francis A., additional, Kroeger, Nicolaus, additional, Wagner-Drouet, Eva-Maria, additional, Wulf, Gerald, additional, Marks, Reinhard, additional, Penack, Olaf, additional, Schnetzke, Ulf, additional, Koenecke, Christian, additional, Von Bonin, Malte, additional, Stelljes, Matthias, additional, Glass, Bertram, additional, Baldus, Claudia D., additional, Vucinic, Vladan, additional, Mougiakakos, Dimitrios, additional, Topp, Max, additional, Wolff, Daniel, additional, Schroers, Roland, additional, Thomas, Simone, additional, Beelen, Dietrich W., additional, Lengerke, Claudia, additional, and Dreger, Peter, additional

Published
2021
Full Text
View/download PDF

47. Comparison Between 5-Azacytidine Treatment and Allogeneic Stem-Cell Transplantation in Elderly Patients With Advanced MDS According to Donor Availability (VidazaAllo Study)

Author

Kröger, Nicolaus, primary, Sockel, Katja, additional, Wolschke, Christine, additional, Bethge, Wolfgang, additional, Schlenk, Richard F., additional, Wolf, Dominik, additional, Stadler, Michael, additional, Kobbe, Guido, additional, Wulf, Gerald, additional, Bug, Gesine, additional, Schäfer-Eckart, Kerstin, additional, Scheid, Christof, additional, Nolte, Florian, additional, Krönke, Jan, additional, Stelljes, Matthias, additional, Beelen, Dietrich, additional, Heinzelmann, Marion, additional, Haase, Detlef, additional, Buchner, Hannes, additional, Bleckert, Gabriele, additional, Giagounidis, Aristoteles, additional, and Platzbecker, Uwe, additional

Published
2021
Full Text
View/download PDF

48. Low Soluble Programmed Cell Death Protein 1 Levels After Allogeneic Stem Cell Transplantation Predict Moderate or Severe Chronic GvHD and Inferior Overall Survival

Author

Kordelas, Lambros, Buttkereit, Ulrike, Heinemann, Falko M., Horn, Peter A., Giebel, Bernd, Beelen, Dietrich W., Reinhardt, H. Christian, and Rebmann, Vera

Subjects
Adult, Male, Time Factors, inhibitory co-receptor, Immunology, Programmed Cell Death 1 Receptor, Medizin, Down-Regulation, Graft vs Host Disease, Medizinische Fakultät » Universitätsklinikum Essen » Institut für Transfusionsmedizin, soluble PD-1, Risk Assessment, Severity of Illness Index, Young Adult, Predictive Value of Tests, Risk Factors, immune system diseases, PD-1, graft-versus-host disease, Humans, Transplantation, Homologous, Prospective Studies, ddc:610, allogeneic hematopoietic stem cell transplantation, immune checkpoint, Original Research, Aged, Hematopoietic Stem Cell Transplantation, Middle Aged, RC581-607, Medizinische Fakultät » Universitätsklinikum Essen » Klinik für Hämatologie und Stammzelltransplantation, Treatment Outcome, surgical procedures, operative, Case-Control Studies, Hematologic Neoplasms, Female, GvHD biomarker, Immunologic diseases. Allergy, Biomarkers
Abstract

Programmed cell death protein-1 (PD-1) is an inhibitory co-receptor required for regulating immune responsiveness and maintaining immune homeostasis. As PD-1 can be released as bioactive soluble molecule, we investigated the clinical significance of soluble PD-1 (sPD-1) after allogeneic hematopoietic stem cell transplantation (HSCT) regarding graft-versus-host disease (GvHD), relapse, and overall survival (OS) in a mono-centric cohort of 82 patients. Compared to pre-HSCT and to healthy controls, post-HSCT sPD-1 plasma levels were significantly increased during an observation time of three months. Univariate analysis revealed that low sPD-1 plasma levels at month one, two or three post HSCT were associated with acute GvHD grade III-IV, the onset of moderate/severe chronic GvHD (cGvHD) and inferior OS, DFS, and TRM, respectively. No relationship was detected to relapse rates. sPD-1 plasma levels were significantly increased in ATG-treated patients compared to ATG-untreated patients. Multivariate analysis revealed that a low sPD-1 plasma levels status at one or two month(s) after HSCT is an independent indicator for inferior OS, DFS, or TRM. A low sPD-1 plasma levels status at month three post HSCT is predictive for the onset of moderate/severe cGvHD. Thus, our study pinpoints the soluble inhibitory co-receptor PD-1 as a promising candidate molecule for the prediction of clinical HSCT outcome. OA Förderung 2021

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results